YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. - Wikidata - wikimedia - TriplyDB

YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients.

YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients.

http://www.wikidata.org/entity/Q35119058

about

Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.Bioinformatics analysis to screen the key prognostic genes in ovarian cancer Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma Bioinformatic analysis of cis-regulatory interactions between progesterone and estrogen receptors in breast cancer.Intraovarian control of early folliculogenesis YAP regulates S-phase entry in endothelial cells Expression of Yes-associated protein in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients.The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma.Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis.YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression.Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway Bioinformatic Studies to Predict MicroRNAs with the Potential of Uncoupling RECK Expression from Epithelial-Mesenchymal Transition in Cancer Cells.Nuclear localization of TEF3-1 promotes cell cycle progression and angiogenesis in cancer.Overexpression of TAZ promotes cell proliferation, migration and epithelial-mesenchymal transition in ovarian cancer.Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer TAZ promotes cell growth and inhibits Celastrol-induced cell apoptosis.miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.Loss of YAP1 defines neuroendocrine differentiation of lung tumors.Splice variant insertions in the C-terminus impairs YAP's transactivation domain.YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo The Hippo pathway in chemotherapeutic drug resistance.Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.YAP/TAZ at the Roots of Cancer.Hippo vs. Crab: tissue-specific functions of the mammalian Hippo pathway.Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma.Akt and Hippo Pathways in Ewing's Sarcoma Tumors and Their Prognostic Significance Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.Sphingosine-1-phosphate promotes ovarian cancer cell proliferation by disrupting Hippo signaling USP21 regulates Hippo pathway activity by mediating MARK protein turnover.Correction: YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients.Recent Advances in Understanding Cholangiocarcinoma.Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer.The polycystic ovary syndrome-associated gene Yap1 is regulated by gonadotropins and sex steroid hormones in hyperandrogenism-induced oligo-ovulation in mouse.Overexpression of TEAD4 in atypical teratoid/rhabdoid tumor: New insight to the pathophysiology of an aggressive brain tumor.Reply: YAP is a Key Factor to Improve the Management of Cancer Treatments.The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression.TEAD4 exerts pro-metastatic effects and is negatively regulated by miR6839-3p in lung adenocarcinoma progression.

P2860

Q28256045-8A0BF952-96FD-471C-AE6D-8F9FFF3F1CE9 Q28550863-68E2BCE5-CDB3-4F45-BC9D-7B6F0DEB9515 Q30369861-B826D995-A933-4405-AC23-C8F7C491F417 Q33560308-31295DE2-A3BA-4AA5-984F-3F78F228B9E1 Q33672296-C47F2ECC-ECD1-482C-A503-D497C66DFF06 Q34568706-E70BBB7D-C919-42C5-967E-1E42F5F031ED Q35024088-74753FF7-149E-4413-B67A-333AC13C49DE Q35031979-DEF8881E-F804-404A-80F3-1D50009C4B18 Q35173737-E311D535-37D4-41CE-A87B-568BDE1F3138 Q35536511-E640C58E-C8B4-402F-9B31-EDB89444F06E Q35742770-8DD16670-6EE9-42A5-981B-7D22BCD9F81E Q35752339-D85F1F18-161C-450E-AE56-411DC7925DC0 Q36086980-0B95FC16-7469-4DE4-BCA8-798778B4BCC3 Q36689006-4564BAC8-7F64-4737-B736-E345305C2DAD Q36921794-996D6379-A47C-4F88-8BB3-D0A084D0CB19 Q37046471-79863829-5428-46FC-9D6A-426A66A48670 Q37203968-E047804C-62DB-4B4A-A7B0-71E93B8A6B3F Q37229782-8A7A511E-C823-4EBC-A8F2-8DF25DCFFB6C Q37294250-0AB2C3C6-0D4B-4EAE-A040-E6B4150ECC1E Q37295543-E0DF9017-BBF0-4C97-A567-D0B556A435F1 Q37375274-272C12BB-25A9-4667-9C7F-64C608F27389 Q37524477-F8C29A36-00B8-4155-BD53-334CBEC71442 Q37697120-526104AF-100B-4D93-9A5F-0E90F19E5D2D Q38263091-170520DC-6D1A-409E-9B99-D8CF0FE92E23 Q38708969-661BEBFF-2DD1-419A-B60C-289F524962F6 Q38864941-B5E7DB80-9D34-4555-8893-DD6B06A79488 Q39081825-7439368B-E977-49F5-935D-4E9226FACF8B Q41345470-C401F10B-09DF-4290-A5B6-4B3C18362A9F Q41364679-B9B8D1DC-6051-4E6F-A90F-CBA1532B9192 Q41484257-74229E79-763B-46B0-AA17-8E337A7AAAE5 Q41839687-62CB5F67-D3BE-41DB-B9B4-258798485D7A Q42080281-67E24454-ACD0-495F-8291-8C2B6C444E93 Q42934599-1216849A-9089-4828-9272-29283D8E9DEF Q47165549-3BB49098-F59A-4FCF-AF1F-6CD2941CC2CD Q47169186-A7EE55CC-3718-4798-B9D4-266267733840 Q47624852-9DB2BCE9-2FB2-4CDD-ACE2-840D225BF200 Q48396105-2DD3A6EE-B8B9-4BCF-A013-D5AE826E74C2 Q50012871-5B5C00D6-F83F-4BD0-BD89-29A9A21EBBB1 Q51011206-987C7A63-94EA-4501-B180-9505D62DA3D8 Q52581038-BB5F8784-3CF2-4E8A-A631-618732210480

P2860

YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients.

http://www.wikidata.org/entity/Q35119058

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

YAP promotes ovarian cancer ce ...... s for ovarian cancer patients.

@ast

YAP promotes ovarian cancer ce ...... s for ovarian cancer patients.

@en

type

label

YAP promotes ovarian cancer ce ...... s for ovarian cancer patients.

@ast

YAP promotes ovarian cancer ce ...... s for ovarian cancer patients.

@en

prefLabel

YAP promotes ovarian cancer ce ...... s for ovarian cancer patients.

@ast

YAP promotes ovarian cancer ce ...... s for ovarian cancer patients.

@en

P1433

Q35119058-A727D91E-F849-4958-867C-434861C08E47

P1476

Q35119058-F52C0BCB-0945-4A98-AC91-81B9A8D700DC

P2093

Q35119058-239CDA14-CB96-4635-8728-FD76A9C84A01

Q35119058-3E2AA70F-508E-4A38-8210-E91E2268F104

Q35119058-597F1CA7-2AFC-49EE-89FF-B631354FD2FD

Q35119058-738DCC32-23CA-478C-B35F-C4785EB9EE5A

Q35119058-74033865-34DE-4517-AA25-AE9BD5200B5C

Q35119058-D3CA2D03-3A1F-4A27-9B68-754CAB046679

Q35119058-E7A7302C-6A19-4D99-9B4E-995772E7E428

P2860

Q35119058-03D7866A-9170-4DD9-B3FA-E7286DD07362

Q35119058-05418D2B-FED2-47EA-ABA3-48E532441088

Q35119058-0A22A40B-9FB8-46F0-82CB-9D5D549D6A59

Q35119058-0FDCD325-3452-437B-99CC-D52518D45AE7

Q35119058-1BB11081-BAE0-48D8-8C91-92833B8010B2

Q35119058-1E080B4B-C6FE-49D2-B85E-42AF2AE8B21A

Q35119058-1F33A283-04C9-49EF-BBF0-B530ED738F27

Q35119058-23C8B2C1-4FC9-4313-8A6F-ADACC61692A4

Q35119058-280C0F74-7942-4C66-A482-0757ABB9E711

Q35119058-3C36FBD4-066F-4116-9D55-9708B8AC0835

P304

Q35119058-0BF4137E-C227-4302-83BA-CCA6DD57817A

P31

Q35119058-5F207EE7-492A-4047-BF7D-907962DB3310

P356

Q35119058-969A3B57-F18F-482D-96CA-30B370035579

P407

Q35119058-3C8A2AE7-0755-44A1-98E7-97DFB2ACB699

P433

Q35119058-007AF89D-125C-4178-9371-4F40B17F0ED6

P478

Q35119058-A6FB51D3-2491-4372-B259-EA77F868DE7F

P577

Q35119058-B6B8DDB7-B74C-4772-94D2-764B37DED38C

P5875

Q35119058-7B390934-8AD9-416B-827E-4D5A8CED3AD0

P698

Q35119058-EC04D607-2E15-4783-B6E0-3AFDB30A56BD

P921

Q35119058-E7D9BD1F-4F0D-4C12-98C5-D22FA2D0B3A7

P932

Q35119058-B07E7A17-15FB-47D5-9282-03B03663D09F

P356

JOURNAL.PONE.0091770

P1433

P1476

YAP promotes ovarian cancer ce ...... s for ovarian cancer patients.

@en

P2093

Heng-Yu Fan

http://www.w3.org/2001/XMLSchema#string

Ming Li

http://www.w3.org/2001/XMLSchema#string

Ting Chang

http://www.w3.org/2001/XMLSchema#string

Wenhui Li

http://www.w3.org/2001/XMLSchema#string

Yan Xia

http://www.w3.org/2001/XMLSchema#string

Yingmei Wang

http://www.w3.org/2001/XMLSchema#string

Yixiong Liu

http://www.w3.org/2001/XMLSchema#string

P2860

A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control

TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway

TEAD mediates YAP-dependent gene induction and growth control

A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator.

Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP

TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm

Expression of Yes-associated protein in common solid tumors

Structural basis of YAP recognition by TEAD4 in the Hippo pathway

WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus

P304

e91770

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0091770

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260759352

http://www.w3.org/2001/XMLSchema#string

P698

24622501

http://www.w3.org/2001/XMLSchema#string

P921

P932

3951505

http://www.w3.org/2001/XMLSchema#string